Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Aditxt Inc
(NQ:
ADTX
)
0.1111
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aditxt Inc
< Previous
1
2
3
4
5
6
7
Next >
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024
September 27, 2024
From
Aditxt, Inc.
Via
Business Wire
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Acquisition Target Files Preliminary Proxy Seeking Stockholder Approval
September 24, 2024
Via
Investor Brand Network
Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt
September 24, 2024
From
Aditxt, Inc.
Via
Business Wire
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Subsidiary Signs Agreement with Evofem Biosciences Inc. (OTCQB: EVFM) Involving Unique Endometriosis Diagnostic Test
September 20, 2024
Via
Investor Brand Network
Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025
September 20, 2024
From
Aditxt, Inc.
Via
Business Wire
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Enters into Second Amendment to Amended and Restated Merger Agreement with Evofem
September 09, 2024
Via
Investor Brand Network
Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024
September 09, 2024
From
Aditxt, Inc.
Via
Business Wire
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Seeks Grant Funding to Advance Early Detection, Management of Prostate Cancer
September 04, 2024
Via
Investor Brand Network
Aditxt Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic® Prostate Test, Targeting Early Detection in High-Risk Patients
September 04, 2024
From
Aditxt, Inc.
Via
Business Wire
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Announces Participation at H.C. Wainwright 26th Annual Global Investment Conference
August 29, 2024
Via
Investor Brand Network
Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024
August 29, 2024
From
Aditxt, Inc.
Via
Business Wire
BioMedNewsBreaks — Evofem Biosciences Inc. (EVFM) Subsidiary Appoints Industry Veteran as Subsidiary President
August 26, 2024
Via
Investor Brand Network
Aditxt’s Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™)
August 26, 2024
From
Aditxt, Inc.
Via
Business Wire
TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX), Appili Therapeutics (TSX: APLI) (OTC: APLIF) Enter Third Amending Agreement
August 21, 2024
Via
Investor Brand Network
Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics
August 21, 2024
From
Aditxt, Inc.
Via
Business Wire
BioMedNewsBreaks — Evofem Biosciences Inc. (EVFM) Releases Second-Quarter 2024 Financial Results, Company Update
August 14, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Releases Report on Annual Shareholders’ Meeting Activity
August 13, 2024
Via
Investor Brand Network
Aditxt Announces the Successful Passage of all Proposals at Recent Annual Shareholders’ Meeting, Setting the Stage for 2024 and 2025 Strategic Plans
August 13, 2024
From
Aditxt, Inc.
Via
Business Wire
Aditxt Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
August 09, 2024
From
Aditxt, Inc.
Via
Business Wire
TechMediaBreaks – Aditxt Inc. (NASDAQ: ADTX) Enters into $1.2M Registered Direct Offering Agreement
August 09, 2024
Via
Investor Brand Network
Aditxt Announces $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
August 09, 2024
From
Aditxt, Inc.
Via
Business Wire
TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Submits Proposal to CDMRP for Ovarian Cancer Detection Research Award
August 07, 2024
Via
Investor Brand Network
Aditxt Subsidiary Pearsanta Seeks Clinical Trial Translational Endpoints Research Award for Early Detection of Ovarian Cancer
August 07, 2024
From
Aditxt, Inc.
Via
Business Wire
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX), Appili Therapeutics Sign Second Amendent to Acquisition Agreement
July 25, 2024
Via
Investor Brand Network
Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st
July 25, 2024
Live moderated video webcast with Evofem management on Thursday, August 1 at 10:30am ET
From
Virtual Investor Conferences
Via
GlobeNewswire
Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition
July 25, 2024
From
Aditxt, Inc.
Via
Business Wire
BioMedNewsBreaks — Evofem Biosciences Inc. (EVFM) Inks Middle East License, Supply Agreement for Proprietary Birth Control Product
July 23, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX), Evofem Biosciences (EVFM) Announce Amended, Restates Merger Agreement
July 17, 2024
Via
Investor Brand Network
Aditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 Closing
July 17, 2024
From
Aditxt, Inc.
Via
Business Wire
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX), Evofem Biosciences (EVFM) Announce Market Partnership with Hello Alpha
June 27, 2024
Via
Investor Brand Network
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.